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Patients with visceral leishmaniasis (VL)–human immunodeficiency virus (HIV) coinfection 
experience increased drug toxicity and treatment failure rates compared to VL patients, 
with more frequent VL relapse and death. In the era of VL elimination strategies, HIV 
coinfection is progressively becoming a key challenge, because HIV-coinfected patients 
respond poorly to conventional VL treatment and play an important role in parasite 
transmission. With limited chemotherapeutic options and a paucity of novel anti-parasitic 
drugs, new interventions that target host immunity may offer an effective alternative. In 
this review, we first summarize current views on how VL immunopathology is significantly 
affected by HIV coinfection. We then review current clinical and promising preclinical 
immunomodulatory interventions in the field of VL and discuss how these may operate 
in the context of a concurrent HIV infection. Caveats are formulated as these inter-
ventions may unpredictably impact the delicate balance between boosting of beneficial 
VL-specific responses and deleterious immune activation/hyperinflammation, activation 
of latent provirus or increased HIV-susceptibility of target cells. Evidence is lacking to 
prioritize a target molecule and a more detailed account of the immunological status 
induced by the coinfection as well as surrogate markers of cure and protection are 
still required. We do, however, argue that virologically suppressed VL patients with a 
recovered immune system, in whom effective antiretroviral therapy alone is not able to 
restore protective immunity, can be considered a relevant target group for an immu-
nomodulatory intervention. Finally, we provide perspectives on the translation of novel 
theories on synergistic immune cell cross-talk into an effective treatment strategy for 
VL–HIV-coinfected patients.
Keywords: visceral leishmaniasis, kala-azar, human immunodeficiency virus, immunotherapy, immunomodulation, 
coinfection, immunity, vaccination
TABLE 1 | The main drugs currently used for treatment of visceral leishmaniasis 
(VL), adapted from Ref. (5).




















Lengthy hospitalization  
(in-patient care)





Uncommon and mild High price
– Nephrotoxicity (limited) Slow iv infusion
Heat instability (<25°C)
Accessibility
Single dose not effective in  
East Africa
Miltefosine Common, usually mild 
and transient
Relatively limited efficacy  
data in East Africa
– Gastrointestinal Possibly teratogenic
– Hepatotoxicity Potential for resistancea





Common Toxicity (Oto- and nephrotoxicity)
– Ototoxicity Resistance readily obtained  
in lab isolates– Nephrotoxicity
– Hepatotoxicity Efficacy variable between and  
within regions (less in Sudan)
Pentamidine Common Low efficacy
– Gastrointestinal Toxicity (diabetes, renal failure)
– Cardiotoxicity Length of treatment
– Pancreatitis
– (Ir)reversible diabetes 
mellitus
aDue to long half-life + low genetic barrier (resistance readily obtained in lab isolates).
iv, intravenous injection; im, intramuscular injection.
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INTRODUCTION
Visceral leishmaniasis (VL), also called kala-azar, is a vector-
borne protozoan infection caused by species of the Leishmania 
donovani complex, which mainly targets tissue macrophages 
of systemic organs, such as spleen, liver, and bone marrow (1). 
Characteristics of the disease include chronic fever, hepatos-
plenomegaly, and pancytopenia (1). Untreated, overt disease is 
universally lethal (1). Zoonotic VL, with dogs as the main reser-
voir, is mainly prevalent in the Mediterranean basin and in South 
America, and is caused by Leishmania infantum. Anthroponotic 
VL is prevalent on the Indian subcontinent and in East Africa 
and is typically caused by L. donovani (2). According to the recent 
World Health Organization (WHO) report, VL is endemic in 75 
countries with an estimated 50,000–90,000 new cases occurring 
each year (3). Ninety percent of the global disease burden occurs 
in just six countries: India, Bangladesh, Sudan, South Sudan, 
Brazil, and Ethiopia (3).
Chemotherapy is currently the sole form of treatment in 
clinical practice. The pentavalent antimonial (SbV) compounds 
[sodium stibogluconate (SSG) commercialized as Pentostam®; 
meglumine antimoniate commercialized as Glucantime®] have 
been the cornerstone of first-line treatment of VL over the last 
70 years. However, these compounds are far from optimal due 
to severe toxicity and the emergence of antimonial resistance 
on the Indian subcontinent (1, 4). Newer drugs that are increas-
ingly used include paromomycin, miltefosine, pentamidine, and 
conventional and liposomal amphotericin B. All these drugs 
have several important disadvantages as shown in Table  1. 
While various combination therapy regimens designed to 
overcome some of the shortcomings are highly efficacious in 
India, disappointing findings on some combination regimens 
have been recently reported in East Africa (5–10). As of today, 
no comparative studies have been conducted to explain this 
geographical difference, but parasite genetic diversity and host 
immune phenotypes are assumed as key factors. Novel chemo-
therapeutic drugs are in the initial development pipeline and 
are, therefore, unlikely to be widely available within the next few 
years. Nevertheless, over 90–95% of immunocompetent patients 
display a good clinical response to currently recommended 
conventional treatment regimens, with treatment unresponsive-
ness, death or severe toxicity observed in less than 5–10% of 
patients (11). Less than 5% of immunocompetent individuals 
who initially cure develop a relapse, most commonly within 
6–12 months after treatment (5). Treatment outcomes, however, 
vary substantially between different geographic regions and 
depend on the drug(s) used, drug exposure, parasite suscepti-
bility to the drug, severity of disease, host immunity, and the 
presence of coinfections (11–13).
Emerging Challenge of VL–HIV Coinfection
Human immunodeficiency virus (HIV) has been identified as 
one of the emerging challenges facing the control of VL (14). The 
immunological status of HIV-infected patients is particularly 
favorable for the multiplication of Leishmania parasites. HIV 
coinfection substantially increases the risk of progression from 
asymptomatic Leishmania infection to active disease (14, 15). On 
the other hand, VL accelerates HIV disease progression towards 
acquired immunodeficiency syndrome (AIDS) and could 
induce expression of latent proviruses (14). HIV has fueled the 
re-emergence of VL in Southern Europe and Brazil, where up 
to 70% of VL cases are associated with HIV infection (7). The 
problem is currently particularly severe in areas such as Northern 
Ethiopia, where up to 30% of all VL patients are coinfected with 
HIV (16). Since 2001, 35 countries have reported between 2 and 
30% of VL cases as coinfected with HIV, but these percentages are 
most probably underestimations (14). Because the disease affects 
the most poor and most neglected patients within an already 
neglected disease population, under-reporting in most endemic 
areas is common due to a lack of facilities to diagnose one or 
both of the diseases and to poor reporting systems. Importantly, 
VL–HIV-coinfected patients are also often considered super-
spreaders of VL and, thus, pose a major threat to current elimina-
tion strategies (17).
Since 1996, combined antiretroviral treatment (cART), com-
prising three antiretroviral drugs, constitutes the cornerstone of 
HIV treatment. The treatment options continue to expand with 
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new drugs and co-formulations; by the end of 2016, there were 
40 antiretroviral drugs from six different classes approved by the 
Food and Drug Administration. In most resource-constrained 
settings, the standardized WHO guidelines are used for ART, 
which currently recommends a combination of tenofovir, 
lamivudine, and efavirenz as first-line treatment. WHO recom-
mended first-line regimens have been found highly effective in 
resource-constrained settings (18). The main aim of cART is 
sustainable suppression of HIV replication, and with good adher-
ence, this can generally be achieved, leading to a close to normal 
life expectancy (19).
Visceral leishmaniasis is one of the AIDS-defining conditions, 
requiring anti-leishmanial treatment and cART irrespective of 
CD4+ T cell count (7). Although there are limited in vitro data 
suggesting that HIV-1 protease inhibitors and possibly some 
other antiretroviral drugs might directly exert inhibitory effects 
on Leishmania, there is insufficient evidence for their clinical use 
against VL, and standard ART regimens are currently recom-
mended in VL–HIV coinfection (5). In low income countries, 
this is provided by standardized first- and second-line regimens 
in a public health approach (20, 21).
Increased toxicity and parasitologically confirmed treat-
ment failures (up to 30%) were observed in VL–HIV-coinfected 
patients treated with SbV, with case fatality rates up to 24% 
(14, 16, 22). While liposomal amphotericin B was consist-
ently found to have excellent tolerability, VL cure rates in 
HIV-coinfected individuals have been rather disappointing in 
East Africa. For example, at a total dose of 30 mg/kg, around 
16% of primary VL and 56% of VL relapse cases demonstrate 
parasitological failure in northern Ethiopia (16). WHO now 
proposes a total dose of 40 mg/kg (7, 23, 24). Experience with 
miltefosine in VL–HIV coinfection is limited, but suggests 
moderate efficacy and an acceptable toxicity profile (22, 25–28). 
To date, only one clinical trial in HIV-coinfected patients has 
been conducted with miltefosine, with 18% of patients display-
ing initial parasitological treatment failure and 25% relapsing, 
although deaths were excluded (22). The role of combination 
therapy in VL–HIV coinfection is currently under exploration 
in clinical trials in India and East Africa.
While in Europe widespread use of cART has resulted in a 
pronounced (i.e., 60%) reduction in the incidence of VL–HIV 
coinfection, relapse in coinfected subjects remains substantial 
at up to 60% after 1 year (14, 29, 30) and secondary prophylaxis 
has only a partial effect (31). In a pentamidine secondary 
prophylaxis trial in Ethiopia, the relapse-free survival rate at 
2  years was only 58.3% (32). Even with access to all current 
chemotherapies, the prognosis in VL–HIV coinfection remains 
dire. Currently, it is believed that VL can only be effectively 
treated in HIV patients before profound immune deficiency has 
developed.
Visceral leishmaniasis–HIV coinfection has a number of 
unique clinical and immunological features. In contrast to many 
other HIV-associated opportunistic infections, CD4+ T  cell 
reconstitution is severely delayed (even if virological suppres-
sion is reached) and the immune reconstitution inflammatory 
syndrome to a Leishmania infection after initiation of cART 
appears relatively rare, indicating a persistent suppression of host 
immunity (33, 34). Atypical clinical presentations can occur and 
amastigotes have been detected in tissues such as the intestine, 
where parasites are mostly undetectable in the immunocompetent 
host (14, 35). After clinical remission, parasitemia also appears to 
persist, at least intermittently (36). A chronic/intermittent course 
of VL lasting several years has been described, labeled as “active 
chronic visceral leishmaniasis” (36). Consequently, HIV-infected 
patients will develop multiple VL relapses and often become pro-
gressively more difficult to treat, ultimately leading to a stage of 
complete treatment unresponsiveness. Hence, there is an urgent 
need for innovative and effective alternative therapies against 
VL–HIV coinfection.
Promising Role of Immunomodulatory 
Therapy
It has become increasingly clear that the host immune response is 
a critical factor determining VL treatment response and control, 
acting in synergy with anti-leishmanial drugs (37). This implies 
that in immunosuppressed individuals, targeting parasites alone 
with conventional anti-leishmanial drugs but without enhanc-
ing the immune response might simply not be sufficient. This 
interaction between drugs and the immune system was first sug-
gested in animal models of VL, where the efficacy of pentavalent 
antimony (Sbv) was lower after T  cell depletion (38). This was 
probably related to the decreased cellular uptake of SbV into 
interferon-gamma (IFNγ) activated macrophages, where it is 
normally converted intracellularly into its active trivalent form 
(SbIII) (4). While this finding should be extrapolated with caution, 
this mechanism may explain the observations that immunocom-
promised patients with VL failed to respond to antimonial drugs.
Immunotherapy is defined as the use of biological mol-
ecules or pharmacological compounds to modulate immune 
responses directly or in combination with drugs. A combination 
of immunomodulatory and direct anti-parasitic drugs could 
enhance the efficacy of chemotherapy and even prevent drug 
resistance (39). On top of its successful use in treating several 
non-infectious disorders (e.g., cancer, rheumatoid arthritis, etc.), 
the use of immune-based combination therapy is increasingly 
being explored in infectious diseases, such as tuberculosis (40) 
and leprosy (41). Despite several candidates being in the drug 
development pipeline, there are no immunotherapeutic agents or 
vaccines against VL currently registered for human use in routine 
clinical practice due to multiple reasons (e.g., high costs of clinical 
trials, limited and remote patient populations, ineffectiveness, 
safety concerns) (42). Experimental immune-based approaches 
are also being explored in the domain of HIV, where many 
have reached Phase I and some Phase II clinical trials but as of 
today have failed to provide enough immune restoration, potent 
effectiveness, sustainable benefits, delay of clinical progression, 
or good safety profiles (40, 43–46). However, VL–HIV-coinfected 
patients are often excluded or neglected in such studies, although 
both individual patients as well as public health approaches in 
general could benefit from these interventions.
Here, we first summarize current views on how host immunity 
against VL is affected during HIV coinfection, and then discuss 
the potential of current immunomodulatory therapies against VL 
FIGURE 1 | Current views on synergistic mechanisms in T cell immunity against visceral leishmaniasis (VL) due to human immunodeficiency virus (HIV) coinfection 
inciting persistent viral and parasite replication in VL–HIV-coinfected patients. APC, antigen-presenting cell; Th, T-helper; GALT, gut-associated lymphoid tissue; CTL, 
cytotoxic T cell; IL, interleukin; ART, antiretroviral therapy; IFN, interferon; LPS, lipopolysaccharide; TNF, tumor necrosis factor.
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in the context of concurrent HIV infection (both human studies 
and promising experimental approaches, excluding prophylactic 
studies). In particular, key targets and potential caveats are 
emphasized to guide future research on immunomodulatory 
therapies against VL and support the inclusion of HIV-coinfected 
patients in clinical research.
IMMUNOPATHOGENESIS OF  
VL–HIV COINFECTION
Macrophages represent an important common reservoir for HIV 
and Leishmania and serve as vehicles that disseminate both virus 
and parasite throughout the host. In addition, both pathogens 
may interact with each other to exacerbate immune suppression 
(Figure  1). In fact, both pathogens severely alter the antigen 
processing and presentation capacities of dendritic cells and 
macrophages, and synergistically escape immune surveillance 
using an array of strategies yet to be fully understood (47).
The control of VL in experimental models has been robustly 
associated with a strong T helper 1 (Th1) immune response, with 
large amounts of IL-2 and IFNγ (48) (Figure 1). In addition, a 
M2 polarization of macrophages has been associated with sup-
pression of cell-mediated immunity, which confers susceptibility 
to intracellular infection. However, the immune mechanisms 
modulating VL in murine models or humans differ significantly. 
Human studies have shown a Th1/Th17 protective pattern 
with a somewhat different T  cell functionality compared to 
experimental models, but lack comprehensive longitudinal data 
(49, 50). CD8+ T  cells have also been shown to produce IFNγ 
that can contribute to VL control (51). The immunosuppressive 
effects of IL-10, and the regulatory role of other cytokines such as 
IL-27, have been implicated in the development of the different 
clinical pictures (50). Impaired neutrophil effector function has 
also been suggested to play a key role in the pathogenesis of VL 
(52). Partly due to the lack of good animal or in vitro models, 
it is currently unknown whether and how these protective and 
5
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immunosuppressive patterns of VL are modulated by HIV and 
ART and how they define the pertinent clinical outcomes of 
VL–HIV patients.
Human immunodeficiency virus-1 causes a general pro-
found impairment of cell-mediated immunity with low levels 
of CD4+ Th1 cells, the main protective cells in VL (Figure 1). 
HIV also skews the host immunity toward a Th2 response that 
only becomes affected at the later stages of the viral infection, 
potentially provoking parasite replication. Th17  cells are also 
associated with protection in VL, but are highly permissive 
to HIV infection. Their frequency is significantly and prefer-
entially reduced in the gastrointestinal tract, even in patients 
with undetectable plasma viral load under ART (53). Depletion 
of Th17 cells from the gut-associated lymphoid tissue together 
with a series of immunopathological events occurring at the 
gastrointestinal tract mucosa leads to microbial translocation 
and consequently higher non-specific immune activation and 
hyper-inflammation (54). This microbial translocation has been 
postulated as one of the factors causing non-specific early T cell 
exhaustion and senescence (55), which may further weaken 
protective immunity toward VL. Likewise, VL was reported 
as an independent cause of increased non-specific immune 
activation, T cell senescence and the lack of immune recovery 
in virologically suppressed coinfected HIV patients (56, 57). 
In line with T cell exhaustion, chronic immune activation was 
recently associated with recurrent relapse of VL in HIV patients 
(58). Recent research in VL–HIV patients also suggested that 
weak antigen-specific functional responses or proliferation of 
T cells after in vitro stimulation was an important predictor of 
relapse (59). Despite the pivotal role of CD8+ T  cells in viral 
and parasite clearance, their contribution in VL–HIV control 
and level of exhaustion remains unknown. Likewise, it is still 
unclear as to what impact Leishmania infection could have on 
the capacity of resting memory CD4+ T cells to act as a stable 
reservoir of latent HIV infection. What impact a spike in viral 
replication may have on anti-leishmanial immunity (e.g., by 
bystander activation of Leishmania-specific memory cells) also 
remains unknown (60, 61).
The consequences of infection by two immune-suppressive 
pathogens could, therefore, be a symbiotic and persistent 
incapacitation of the host’s immune system, favoring a state 
of immunological anergy, ultimately being fatal to the patient. 
A better understanding of the immune response against 
Leishmania infection in HIV-coinfected patients is crucial to 
establish a rational approach for immunomodulatory therapy.
STATUS OF IMMUNOTHERAPEUTIC 
INTERVENTIONS IN HUMAN VL AND 
THEIR APPLICATION IN HIV PATIENTS
Due to the lack of a protective role of anti-Leishmania antibodies 
in early studies, passive immunization was not further explored, 
while active immunization with immunomodulators and vac-
cine therapy was investigated (62). Early studies by Murray et al. 
(38, 63, 64) showed the therapeutic utility of interleukin-2 (IL-2), 
IL-12, interferon-gamma (IFNγ), and granulocyte–monocyte 
colony-stimulating factor (GM-CSF) in murine VL models. 
Although the Th1/Th2 dichotomy of immunity to VL is not 
fully upheld in humans, clinical immunotherapeutic studies on 
VL patients have been skewed toward Th1-associated cytokine-
adjuvant therapy and are discussed below (see Table  2). For 
VL–HIV coinfection, only five published case reports using 
recombinant IFNγ, IL-2, and GM-CSF combined chemotherapy 
were found in literature (see Table 2).
Interferon-γ
There has been limited success in small-scale clinical trials with 
combined therapy of IFNγ and SbV for treating VL. This com-
bination therapy displayed stronger parasitological and clinical 
cure rates in VL patients (mainly children) from Brazil, Kenya 
and India compared with the drug alone, but these studies had 
several limitations (see Table 2 for details). In a subsequent larger 
randomized controlled trial (RCT) in India, these improved 
treatment outcomes could not be confirmed (70). Importantly, 
treatment response in this particular study was generally poor as 
drug resistance was emerging in that region.
There are a few case reports, mostly from the pre-ART era, 
providing information on whether IFNγ can be safely adminis-
tered in VL–HIV patients (see Table  2), which is of relevance 
since IFNγ also has a vital but ambiguous role in the pathogenesis 
of HIV (78). IFNγ appeared to be fairly well tolerated but showed 
inconclusive results (73, 74, 79). In one old case report of a patient 
with VL–HIV coinfection, acceleration of Kaposi’s sarcoma has 
been reported (75). The therapeutic potential of IFNγ to treat 
HIV coinfections was supported by two Phase II trials, evaluating 
adjunctive IFNγ to improve treatment response to antifungals in 
HIV patients with cryptococcal meningitis (80, 81). However, in 
the early 1990s, a multicenter clinical trial of SSG plus IFNγ for 
VL in HIV-coinfected patients in Spain was suspended following 
an interim analysis indicating that there was an excess of severe 
secondary effects and no benefit over drug alone (79). The find-
ings itself have never been published but suggested a limited value 
of IFNγ therapy for VL–HIV coinfection.
Granulocyte–Macrophage Colony-
Stimulating Factor
Granulocyte–monocyte colony-stimulating factor can inhibit 
the intracellular replication of protozoa such as Leishmania. The 
justification to explore GM-CSF as immunotherapeutic agent 
stems from documented effects, such as monocyte mobilization, 
macrophage activation, the production of pro-inflammatory 
cytokines, and amelioration of neutropenia (63). GM-CSF 
combined with SbV was successfully explored in 20 neutropenic 
VL patients in Brazil. All responded well to VL treatment, neutro-
penia rapidly improved and secondary infections decreased (68) 
(Table 2). The authors did, however, not include a control arm, 
making it unclear whether the effect of GM-CSF, if any, could be 
due to the reversal of neutropenia (and might hence not apply in 
those without neutropenia) or whether other mechanisms were 
involved. On the other hand, in vitro studies have recently sug-
gested that GM-CSF could contradictory promote Leishmania 
growth by inducing monocyte proliferation and induction of 
intracellular dNTP production (82), but whether this would also 
occur in humans remains unknown.













(65) Brazil; 1990; 
case series
(1) SSG-unresponsive  
VL (n = 8); <18 years (8/8);  
Mean age: 6.5 years
SSG 20 mg/kg IFNγ (100–400 µg/m2 
for 10–40 days)
6/8 cured EOT (75%)
No relapse during study  
period
Higher cure rates in  




(2) Severely ill primary  
VL (n = 9) <18 years (8/9)
Mean age: 9.8 years
SSG 20 mg/kg IFNγ (100–400 µg/m2 
for 10–40 days)
8/9 cured EOT (89%)
No relapse during study  
period
(66) Brazil, 1993; 
case series
(1) Primary VL (n = 8)
Predominantly children
Median age: 5 years










Cure 12 M: 8/8 (100%)
1/8 relapsed
12/14 cured
Both groups: more  
severe cases than  
in 1990
Cure 12 M: 9/14 (64%)
6/12 relapsed




(1) Primary VL (n = 10)
<18 years: 7/10

















lerated response with 
SSG + IFNy
(68) Brazil; 1994; 
RCT
(1) 10 neutropenic primary VL












Study focused on hema-
tological evaluation and 
secondary infections
Secondary infections oc-
curred in 3 GM-CSF and 
in 8 placebo recipients
(69) India; 1995; 
RCT
(1) Primary VL (n = 16)
Mean age 21 years (range 6–52)
(2) Primary VL (n = 15)
Mean age 27 years (range 5–58)
SSG 20 mg/kg 
for 20–30 days
IFNγ (100 µg/m2) Cure D10: 10/15 (63%)
Cure D20: 14/15 (93%)
Cure D30: 15/15 (100%)
Cure M6: 13/15 (87%)
D10 and D20 difference 
statistically significant
No relapse up to M24
SSG 20 mg/kg 
for 20–30 days
/ Cure D10: 1/15 (7%)
Cure D20: 6/15 (40%)
Cure D30: 11/15 (73%)
Cure M6: 9/15 (60%)
Treatment was discon-
tinued early in the 14 
IFNγ treated responders 
after D20
(70) India, 1997 (1) Primary VL (n = 52)
Mean age 20 years; 60% male
(2) Primary VL (n = 52)
Mean age 18 years; 58% male
(3) Primary VL (n = 52)








 (100 µg/m2  
for 30 days)
IFNγ











6 M cure: 18/50 (36%)
High failure rate with 
standard therapy (SSG-
resistance?)
Differences not  
statistically significant
(71) USA, 2012, 
Phase I RCT
(1) Healthy volunteers (n = 12)
(2) Healthy volunteers (n = 12)











Safe and immunogenic D84: 
10/10
Safe and immunogenic D84: 8/8
Safe and immunogenic D84: 9/9
Subunit vaccine: single  
recombinant fusion 




Adriaensen et al. Immunotherapy VL–HIV Coinfection
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1943
In terms of safety, several older clinical trials of GM-CSF admin-
istration in HIV patients indicated that it might accelerate HIV 
replication (83). By contrast, more recent RCTs have demonstrated 
benefits of using GM-CSF in virologically suppressed patients as an 
adjunct to conventional ART or therapeutic HIV vaccination (83, 
84). This would argue against using GM-CSF in pre-ART patients, 
but might suggest it to be safe in those stable on ART. With regard 












(72) UK, 2016, 
Phase I trial
(1) Healthy volunteers (n = 20)  
n = 5 low dose
n = 15 high dose
/ ChAd63-KH (1 × 1010 
vp or 7.5 × 1010 vp)
Safe and immunogenic D90: 
20/20
Adenovirus vector 
encoding 2 Leishmania 
proteins
Dose escalation study












(2 mg/kg iv 3 
times/week, 
1 week/month)
IFNγ (175 μg/day iv or 
sc for 21 days)






Cure 6M: Only two mild relapses 





Three full-blown AIDS patients Meglumine 
antimoniate 
(dose unknown)
IFNγ (dose unknown) Clinical improvement





































IL-2 (twice/day for 
5 days—7 cycles 
every 4–8 weeks) 
(cycle 1–4: 3MIU; 
cycle 5–7: 6MIU)
No benefit
Increase in Leishmania DNA
IFN, interferon; SSG, sodium stibogluconate; VL, visceral leishmaniasis; EOT, end of treatment.
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GM-CSF therapy of resistant-to-standard-therapy mycobacterial 
infection and pulmonary aspergillosis in HIV patients (85, 86). 
There is a single successful case report on immunotherapy targeting 
primary VL in an Italian AIDS patient, whereby human GM-CSF was 
combined with liposomal amphotericin B (Table 2) (76). Presently 
the evidence for beneficial effects of GM-CSF on HIV disease is 
limited, but GM-GSF adjuvant therapy could provide a potential 
value for treatment of neutropenic VL in stable ART patients.
Interleukin-2
Interleukin-2 induces clonal expansion of specific T  cells; pro-
motes natural killer and CD8+ T cell cytotoxicity, cytokine secre-
tion by Th1, Th2, and Th17  cells; and modulates programmed 
cell death (42). Hence, IL-2 is necessary for the protection against 
Leishmania in immunodeficient mice, in which IL-2 restores the 
activity of SbV (38, 87). The impairment in IL-2 production is also 
one of the first functional defects described in untreated HIV-
positive patients and its administration to boost the quantitative 
and/or qualitative CD4+ T cell restoration in HIV-infected patients 
has been evaluated in Phase I, II and III trials (42). These early 
results provided evidence that IL-2 therapy combined with exist-
ing cART has the potential to enhance quantitative and qualitative 
immune restoration, without triggering HIV replication, even 
when ART alone had failed to do so. However, restoring CD4+ 
T cell counts with IL-2 failed to show long-term clinical benefits 
in two large Phase III clinical trials, ESPRIT and SILCAAT (88). 
IL-2 recipients in the STALWART trial even experienced more 
opportunistic infections, death or grade 4 adverse events during 
IL-2 administration, than those not receiving IL-2 (89).
To date, no clinical trial for rIL-2 administration in VL 
patients has been reported. There has been one case report on the 
use of rIL-2 in a VL–HIV-coinfected patient failing to respond 
to anti-leishmanial and HIV treatment with low CD4 counts 
and incomplete HIV suppression despite ART use (77). This 
report indicated no benefit. Importantly, increased Leishmania 
parasitemia was observed at each rIL-2 cycle, which might have 
favored the progression of HIV infection and possibly explains 
the reported progressive decline in CD4 T cell count (77). In a 
BALB/c mouse model, IL-2 seemed to have a short protective 
effect against VL only at the priming phase, without any lasting 
benefit (90). Such a phase-specific effect could explain the lack 
of long-term clinical benefits. In general, the small therapeutic 
window, critical dosage with potential high toxicity and challeng-
ing treatment conditions suggest IL-2 is an unlikely candidate for 
boosting immunity in VL–HIV-coinfected patients.
Therapeutic Vaccines
Historically, leishmanization (inoculation with live parasites) 
was shown to have benefit for protection against re-infection 
with cutaneous leishmaniasis (CL) and this evidence has driven 
TABLE 2 | Continued
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the search for an effective vaccine against VL (91). Besides 
prophylactic vaccine development, various approaches employing 
therapeutic vaccines have been tested experimentally and clini-
cally; and currently resulted in three licensed vaccines for canine 
VL but none for human VL (92). Therapeutic immunization with 
a first generation vaccine of aluminum hydroxide precipitated 
autoclaved L. major (Alum-ALM)+Bacille Calmette–Guérin 
(BCG) was found clinically effective in CL, mucocutaneous 
leishmaniasis and persistent post-kala-azar dermal leishmaniasis 
(PKDL) cases, with studies progressing to Phase III clinical tri-
als (93–99), but application to VL has not been reported (62). 
Similarly, LeishF1/F2 vaccine (alternatively called Leish-111f), 
a promising second-generation (i.e., recombinant protein) vac-
cine for CL, showed insufficient protection against VL in dogs 
(100). A modified version of these second generation vaccines, 
called LeishF3, which accommodated changes to enhance its 
efficacy against VL has been shown to be safe and immunogenic 
in a Phase I trial in healthy human volunteers, but therapeutic 
trials in patients have not been reported (Table 2) (71). A third-
generation (i.e., DNA-based) adenovirus vaccine (ChAd63-KH) 
was designed to induce Leishmania-specific CD8+ T  cells and 
aimed at therapeutic use in VL/PKDL patients. It was shown 
to be safe and immunogenic in healthy volunteers (72) and is 
currently in Phase II trial in persistent PKDL patients in Sudan.
A careful risk–benefit assessment needs to be made when con-
sidering therapeutic vaccination against VL in HIV patients, with 
depressed immunity. Safety concerns surely exist, but should not 
be overstated and should not impede evaluation of therapeutic VL 
vaccination studies in virally suppressed HIV patients as potential 
benefits can outweigh existing theoretical risks. In essence, these 
patients have a higher risk of developing VL and are most in need 
of an enhanced immune response upon VL development. Post-
marketing trends suggest that routinely used inactivated (non-VL) 
vaccines have similar safety profiles among HIV-uninfected 
and HIV-infected persons on stable ART (101). Although data 
are still limited, HIV-infected individuals who are on ART with 
well-controlled HIV RNA levels and CD4+ T cell counts of >200 
cells/μL (or ≥15%) may even receive indicated live-virus vaccines 
(101). In addition, modern post cART era studies did not indicate 
that vaccines are important triggers of HIV replication or disease 
progression (102). With regard to efficacy, a highly immunogenic 
vaccine will be needed, as well as detailed studies to define the 
optimal timing and dosing for vaccination among those with 
advanced disease. Despite the concerns of depressed immunity and 
sparse efficacy data for other types of vaccines, studies have clearly 
demonstrated the protective benefit of influenza and Streptococcus 
pneumoniae vaccinations even among advanced HIV patients. In 
summary, these data merit a concurrent evaluation of therapeutic 
VL vaccines in coinfected patients who are virologically suppressed 




While both the pharmacokinetics and pharmacodynamics of 
a drug, but also the nature of drug–immune interactions in 
animals and humans may differ considerably, animal models 
may still provide new clues to potential approaches. Here, we 
selected the most promising molecules or interventions for 
their potential in an immunosuppressive environment of the 
coinfected individual and refer to recent review papers for a 
more extensive list (39, 44, 45, 92, 103). The formats discussed 
below are limited to active immunotherapy attempts including 
non-antigen-specific strategies such as cytokines that stimulate 
immunity or suppress the viral replication; antibodies that block 
negative regulatory pathways; and indirect immunomodulation 
(Figure 2). Antigen-specific strategies such as therapeutic vac-
cination and adoptive strategies such as cell therapy are also 
briefly discussed. Whether the molecules listed below could 
serve as putative targets for human immunotherapy remains to 
be demonstrated.
Non-Antigen-Specific Strategies
The above listed clinical trials with cytokine-adjuvant chemo-
therapy were based on limited data from experimental models 
of VL conducted in the 1990s. Our knowledge of immune 
mechanisms has substantially expanded since then. For instance, 
IL-12, a pluripotent cytokine that plays a central role in the initia-
tion/maintenance of Th1 responses and potentiates T cell IFNγ 
production, was shown to have similar effects as IFNγ in both 
CL and VL when injected in mice (64, 104) as well as dogs (105) 
and human PBMC from treated Sudanese VL patients (106). 
Likewise, IL-12 preconditioning of monkeys during acute SIV 
infection markedly delayed disease progression (107). While 
rhIL-12 administration was well tolerated and safe, no evidence 
of improvement in HIV antigen-specific immune response could 
be observed in a Phase I RCT (108). While this suggests that 
IL-12 therapy is unlikely to provide major benefits in the chronic 
phase of an HIV infection, it might still be valuable in the con-
text of opportunistic infections that are best met with Th1-like 
effector immune responses. In line with this, rIL-12-adjuvant 
chemotherapy was successfully evaluated for patients with 
Kaposi’s sarcoma (109). In addition, it has been tested as part 
of a combination therapy for cryptosporidiosis in two AIDS 
patients that demonstrated signs of a brisk immune response 
and consequently symptomatic improvement, but with severe 
side effects that outweighed the clinical benefits (110). Data 
on the role of IL-12 as an immunotherapeutic agent or vaccine 
adjuvant for HIV coinfections could be promising and merits 
further research, although potential broad side effects due to its 
pluripotent role should be limited (e.g., tissue-targeted delivery, 
well-timed short boosting approach, etc.). Unfortunately, the 
incorporation of IL-12 into larger vaccine trials has lagged, 
largely due to the early setback in a renal carcinoma Phase II trial. 
However, the mechanisms underlying the severe acute toxicities 
that led to two deaths and 12 hospitalizations have been ascribed 
to an inappropriate dose and administration schedule (111).
Like IL-12, many chemokines or cytokines contributing 
to protection/pathogenesis of VL are regulated during HIV 
coinfection. For instance, Th17  cells are highly depleted from 
the gut in HIV-infected patients. Recent work in humans has, 
however, demonstrated the importance of IL-17 and IL-22 in 
protection against VL progression from asymptomatic infection 
FIGURE 2 | Overview of described clinical and preclinical immunomodulatory interventions in human visceral leishmaniasis (VL) and their application in (VL)-human 
immunodeficiency virus (HIV) (co)infection. IL, interleukin; IFN, interferon; PD-(L)1, programmed cell death-(ligand)1; GM-CSF, granulocyte–macrophage colony-
stimulating factor; CTLA, cytotoxic T lymphocyte-associated molecule; CD, cluster of differentiation; BCG, Bacillus Calmette–Guérin; Alu-ALM, aluminum hydroxide 
precipitated autoclaved L. major; DC, dendritic cell; GP, Glycoprotein; Ara-LAM, arabinosylated lipoarabinomannan; Pam3Cys, synthetic bacterial lipopeptide; CpG 
Odn, CpG oligodeoxynucleotides; ASA, acetyl salicylic acid; MPL, monophosphoryl lipid.
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to disease (49). In addition, elevated serum IL-27 concentrations 
were linked to severity of VL. IL-27 seems to regulate the Th1/Th17 
profiles in a L. infantum mouse model of VL by suppressing the 
IL-17-induced neutrophil response (112). The IL-27–Th17–IL-17 
axis, thus, seems to be strongly involved in resistance against VL 
and merits further therapeutic exploration, especially in HIV-
coinfected patients with a Th-17-depleted immune response.
Despite the central role of IL-7 cytokine therapy in HIV 
patients in the past, this molecule has not been evaluated in 
VL–HIV-coinfected patients and remains under-investigated in 
experimental models of VL (113). IL-7, like IL-2, has a critical 
role in peripheral T cell homeostasis. IL-7 has, however, a more 
pleiotropic role and was shown to drive CD4+ T cell restoration 
in HIV patients, even when HIV replication is controlled. It is 
also able to promote Th1 responses, enhance memory T  cell 
expansion (on top of naive T cell response), and increase CD8+ 
T  cell counts and cytotoxicity in HIV patients (42). Moreover, 
damage to hepatocytes during full-blown VL may impair IL-7 
production, as IL-7 is also produced by liver cells in response to 
inflammation (114). Recombinant IL-7 administration thus has 
the potential to safeguard the long-term survival of effector CD4+ 
T cells in response to persisting parasites in a VL–HIV coinfec-
tion. However, in the ERAMUNE 01 RCT, rIL-7 and dual ART 
intensification induced an amplification of the HIV reservoir in 
well-controlled HIV patients (115). The authors reasoned that 
this was the result of the expansion of central memory CD4+ 
T cells, carrying HIV DNA, thus limiting this IL-7 based strategy. 
In the context of VL–HIV coinfection, this strategy should only 
be considered if a pronounced clinical benefit to VL treatment 
outweighs its potential negative effects.
Blocking the action of immune-suppressive factors could 
prove more efficient as it might allow restoration of protective 
immunity in a more controlled manner. IL-10 correlates very 
well with the parasite load during VL infection. Moreover, in 
animals, IL-10 blockade (by means of anti-IL-10R or anti-IL-10 
monoclonal antibody) has been proven successful in lowering 
parasite burden when combined with conventional treatment in 
multiple studies in mice (116, 117). These effects were confirmed 
in cultures of splenocytes or PBMCs from Indian and Sudanese 
VL patients (106, 118). However, in immunodeficient mice 
treated with anti-IL-10R monoclonal antibody, Murray et  al. 
were not only able to show an acceleration of SbV-associated kill-
ing, but also reported a >10-fold SbV dose-sparing effect (119). 
Despite the clinical and experimental data suggesting IL-10 as a 
key target in the immunopathogenesis of VL, a clinical trial using 
a monoclonal antibody against IL-10 failed to start following the 
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decision of the company to stop its production (NCT01437020, 
clinicaltrials.gov).
Increased serum IL-10 concentrations are also observed 
in HIV-infected patients with disease progression, in contrast 
to non-progressing patients where levels were stable (120). 
In addition, ART has a clear downregulating effect on IL-10. 
On the other hand, increasing evidence suggests that IL-10 
impacts many aspects of HIV pathogenesis, including the regu-
lation of HIV-specific CD4+ and CD8+ T cell functions, as well as 
modulation of HIV replication in PBMC subsets. Genetic poly-
morphisms in the IL-10 gene promoter that lead to decreased 
IL-10 expression have been associated with more rapid disease 
progression in late stages of HIV infection, suggesting that the 
anti-inflammatory effects of IL-10 may be solely protective in 
the setting of chronic immune activation and blocking IL-10 
function would only make sense in an acute setting (121). When 
considering VL–HIV coinfection, these data would advocate 
the blocking of excessive IL-10 levels during the acute stage of 
VL in HIV patients (in particular pre-ART patients) to allow a 
beneficial acute response which should however be time limited 
to retain the beneficial role of IL-10 in controlling side damage 
of chronic HIV and parasitic infections. To reduce the unwanted 
side effects due to blockage of normal, and beneficial, biologi-
cal activities, novel IL-10 signaling inhibitors with for instance 
shorter half-lives are first needed (122).
The concept of immune exhaustion and senescence as a 
stepwise and progressive loss of T cell function and proliferative 
potential, respectively, and evolving to complete T  cell unre-
sponsiveness has been robustly discussed in the context of HIV 
infection (123). The driving force is believed to be chronic antigen 
exposure and consequently extensive non-specific immune acti-
vation. Increased immune activation in patients on long-term 
suppressive cART has been associated with increased mortality, 
the occurrence of non-AIDS-defining conditions, and a poorer 
recovery in CD4+ T  cell count (124, 125). Similarly, increased 
levels of programmed death-ligand 1 (PD-L1) expression on 
monocytes, B cells, and T cells from untreated HIV patients cor-
related directly with plasma viral load and inversely with CD4+ 
T  cell count (126). This mechanism could partly explain the 
disappointing long-term effects of IL-2 therapy in HIV patients, 
as IL-2 was recently shown to upregulate the PD1–PD-L1/L2 
pathway (127). While the causative factors of immune exhaustion 
or senescence are not completely understood, chronic immune 
activation, residual HIV-replication, and coinfections are likely 
main drivers of this process. Recent studies have also focused on 
the role of this process in the context of VL and other parasitic 
infections, showing an accelerated T cell senescence during VL 
infection (128). Likewise, a parasite-induced T  cell anergy has 
been proposed (128). Hence, a modulatory approach to reverse 
this process or temporarily breaking the regulatory feedback loop 
using antibody therapies targeting PD-1, CTLA-4 or its ligands 
could prove efficient in coinfected individuals with a potential 
double-driven T  cell unresponsiveness. Such an approach to 
reverse the reported T  cell unresponsiveness has proved very 
effective in experimental VL (57, 129–131). In SIV-infected 
rhesus macaques, anti-PD-1 (in the absence of ART) was shown 
to enhance virus-specific CD8+ T  cell activity, to reduce viral 
load, and to prolong survival (46). Similarly, anti-PD-L1 antibody 
therapy showed promising in a recent Phase I RCT on 6 ART 
patients, arguing in favor of its potential use in virologically 
suppressed VL–HIV patients (132). Recently, the major HIV cell 
reservoir was shown to be composed of PD-1+ CD4+ memory 
T  cells, suggesting an additional positive effect of anti-PD-1 
therapy to combat the concomitant HIV infection (133).
Antigen-Specific and Adoptive Strategies
There are multiple studies in which diverse antigens and 
adjuvants showed promising results as immunoprophylactic 
or therapeutic tools in animal models of VL, recently summa-
rized in a review by Jain and Jain (92). Apart from the current 
clinically explored strategies and the safety/efficacy concerns 
in HIV patients (see above), a promising approach would be to 
vaccinate with a non-pathogenic L. tarentolae strain, genetically 
modified to improve its immunogenic potential as a live vaccine 
(134). Likewise, a novel third generation T cell epitope-enriched 
DNA vaccine (LEISHDNAVAX) showed significant efficacy 
when co-administered with a single dose of AmBisome in 
L. donovani-infected mice (135). The vaccine is based on 
minimalistic immunogenically defined gene expression vectors 
encoding five conserved antigens developed for efficient induc-
tion of Th1 immune responses. This candidate vaccine has yet to 
enter clinical Phase I trials.
Another cutting-edge approach to induce antigen-specific 
T  cell immunity is dendritic cell-based immunotherapy 
(103, 136). While macrophages are one destination of 
Leishmania parasites in the human host, dendritic cells can 
also harbor parasites, but in addition present antigen and 
regulate immune mechanism governing control or progression 
of infection. Adoptive transfer of dendritic cells primed with 
different kinds of Leishmania antigens has been shown very 
effective in murine VL, improving both cellular and humoral 
immunity (136). Compared to the modest efficacy of immune 
therapy and therapeutic vaccines against HIV infection, ex vivo 
generated dendritic cell therapeutic vaccines aimed at inducing 
effective HIV-specific immune responses have yielded the best 
results in this field (137). The outcomes of monocyte-derived 
dendritic cell-based therapeutic vaccines still needs optimiza-
tion as functional cure was not reached and most patients 
needed to restart ART, but this method could provide a strong 
immunogenic window for concomitant VL-targeted therapy 
of coinfected individuals. Due to high costs and required 
state-of-the-art equipment, adoptive cell transfer therapy may 
prove difficult to implement in low-resource settings of disease 
endemic countries.
Indirect Strategies
An alternative approach is to indirectly stimulate host immu-
nity to optimize protection against infection. Such indirect 
immunomodulators can be obtained by many different types of 
substances, including natural products that have immunomo-
dulatory activity. Such immunomodulators, however, carry the 
risk of inducing excessive immunopathology and side effects. 
Many compounds have been evaluated in VL animal studies over 
the years, including CpG oligodeoxynucleotides, acetyl salicylic 
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acid and l-arginine (103). Most of these molecules increase 
T  cell activation through enhanced antigen presentation by 
costimulation-based therapy or acting on toll-like receptors 
(TLRs) (e.g., TLR4/GP29 or MPL; TLR2/Ara-LAM, or Pam3Cys). 
This could be particularly beneficial in HIV-coinfected patients, 
as TLR-agonists such as TLR7 or TLR9 agonists have shown 
reduction of viral DNA or the viral reservoir and enhancement of 
HIV-specific CD8+ T cell immunity in experimental and human 
HIV (138, 139). Whether such a multi-TLR targeting approach 
would benefit human VL–HIV patients remains unclear and 
merits further research.
In a similar manner, it has been suggested that TLR4 and 
TLR9, two TLRs contributing to the immune response against 
Leishmania infection, play a role in the anti-leishmanial mecha-
nism of miltefosine (140). An alternative strategy could, thus, 
be to concurrently capitalize on the indirect immunological 
effects of the combined anti-leishmanial drug in a immuno-
chemotherapeutic approach. The relevance and impact of these 
immunomodulatory actions of current anti-leishmanials in 
HIV-coinfected VL patients remains to be determined. Besides 
a direct mechanism of action, anti-leishmanials can increase 
nitric oxide and reactive oxygen species production due to 
activation of infected macrophages, leading to elimination of the 
parasite. This indirect activation of macrophages has been shown 
for amphotericin B (141), miltefosine (142), antimonials (143), 
and paromomycin (144). Induction of macrophage-derived 
cytokine release promoting a Th1 response (IL-2, IL-12, IFNγ) 
has been noted for all conventional anti-leishmanials such as 
amphotericin B (141, 145), miltefosine (142, 145), paromomycin 
(145), and SSG (143, 145), even though contradictory results 
have been reported, e.g., for miltefosine (146). Related to this, 
miltefosine restored IFNγ responsiveness in Leishmania-infected 
macrophages (142). Another immunostimulatory property 
contributing to anti-leishmanial activity is a drug-induced 
increase in macrophage membrane fluidity, ameliorating defects 
in antigen presentation and enhancing T cell stimulation. This 
has been shown after exposure of infected host cells to higher 
concentrations of miltefosine, paromomycin, and SSG (145). For 
both antimonials (147) and miltefosine (148), it has been shown 
that they increase the phagocytic capacity of monocytes and 
macrophages. There are currently no data available whether all 
these effects are clinically relevant in terms of short-term treat-
ment response, relapse, final cure, and the risk of development 
of PKDL. Despite the current lack of data on clinical relevance, 
these background effects should be taken into consideration in 
future combined immuno-chemotherapeutic strategies to incite 
an effective synergistic effect. The general lack of response to 
anti-leishmanial treatment in HIV-coinfected patients and the 
relevance of concomitant cART for the efficacy of current anti-
leishmanials possibly indicate that these indirect effects are not 
negligible for a therapeutic response.
PERSPECTIVES
Despite the growing research in immunotherapy against VL 
(partly reviewed above), no immunotherapeutic approach 
has yet been licensed for use in human VL. HIV-coinfected 
patient groups, in particular, are often excluded from the above 
described clinical intervention studies due to the presumed 
hazards and challenging logistics. Although a vulnerable 
population, we would argue that VL–HIV patients should be 
considered as a relevant target group for an immunomodula-
tory approach against VL due to an intensified defect in T cell 
immunity, dependence of current anti-leishmanial drugs on the 
latter, inadequate treatment outcomes, and higher chronicity 
of the parasitic infection with frequent relapse. In addition, 
HIV-targeted immunomodulatory approaches, despite their 
drawbacks to achieve long-term functional cure in HIV 
patients, might find a temporarily window of opportunity in 
opportunistic coinfections such as VL, where cART alone is not 
able to restore protective immunity. The challenge, however, of 
immunomodulatory therapy in VL–HIV-coinfected patients 
is boosting effective VL-specific T cell responses while avoid-
ing activation of latent provirus and inappropriate immune 
activation (in virologically suppressed ART patients) or HIV 
recrudescence and increased HIV-susceptibility of target cells 
(in unstable HIV/AIDS patients). Clinical trials are a necessity 
to study treatment effects, due to the lack of good animal or 
in vitro models mimicking VL–HIV coinfection.
In Figure  2, we summarized the discussed interventions 
against VL and highlighted those that have also been clinically 
evaluated in the context of HIV. Evidence is lacking to prioritize 
a target molecule, but attempts at immunotherapy in VL–HIV 
patients should best be performed in ART patients with a recov-
ered immune system. Appropriate adjuvants can be included to 
enhance the efficacy of the response, but caution should be taken 
to avoid excessive and broad immune activation. The following 
perspectives are best taken into consideration when designing 
or evaluating an immunomodulatory approach in VL–HIV-
coinfected patients.
Combination Strategies
As current anti-leishmanial drugs are highly dependent on host 
immunity, it is recommended to potentiate chemotherapeutic 
agents with various immunomodulators in HIV-coinfected 
patients. While the increment in immunocompetent patients 
could be potentially low, HIV-coinfected patients are probably in 
more need of a boost in effective T cell immunity against VL to 
decrease the high mortality and treatment failure rates typically 
observed in coinfected patients.
The current clinically explored techniques of single cytokine-
adjuvant therapy in VL have the inherent danger of a very 
pluripotent effect in HIV-coinfected patients, due to the intrica-
cies of cytokine networks, and may unpredictably impact the 
delicate balance between beneficial VL-specific responses and 
deleterious immune activation. Future therapeutic use of broad 
immunomodulators will most likely lead to unwanted side effects 
in coinfected patients until a system-level understanding of their 
mode of action is available and thus a more selective and well-
timed approach can be performed (149). However, they could 
potentially prove valuable as a well-timed adjuvant in a more 
targeted immunomodulatory approach.
The other clinically explored strategy in VL is therapeutic 
vaccination. However, as T cell senescence and exhaustion could 
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have occurred by persistent HIV replication, further stimulat-
ing effector-memory T cells could be futile or even harmful in 
VL–HIV patients. Perhaps a concurrent strategy to reverse this 
T cell exhaustion (e.g., anti-PD-1 therapy) could increase vaccine 
efficacy. It remains to be seen whether VL–based therapeutic vac-
cines deployed in HIV-coinfected patients are safe and whether 
a strong enough response can be induced against VL. In severely 
CD4+ depleted patients in particular, a concurrent need may be 
to first encourage immune reconstitution before vaccination. 
Combination strategies of diverse immunomodulators and drugs 
will, thus, be crucial in these patients to reach an effective treat-
ment, perhaps with a more individualized approach.
Stratification
Among patients with tuberculous meningitis, different inflam-
matory patterns governed by host genetics are recognized, con-
verging on dysregulated levels of TNF. At one end of the extreme, 
a hyper inflammatory phenotype was shown to benefit from 
steroid administration; at the other end, where inflammation is 
inadequate, other immunomodulatory interventions would be 
required (150). In a similar manner, subgroup analyses in HIV-
associated cryptococcal meningitis suggested that the greatest 
benefit of a short-course IFNγ adjuvant therapy was gained among 
patients with a lack of Cryptococcus-specific IFNγ/TNF CD4+ 
T cell responses (151). In most settings, VL–HIV-coinfected indi-
viduals will also be (severely) malnourished upon VL diagnosis, 
and micro- and macro-nutrient deficiency can have profound 
immunological effects. These alterations could critically affect 
the efficacy of any immunomodulatory interventions, yet may 
also provide opportunities for complementary interventions. 
We, therefore, argue that there is a need to assess immune risk 
profiles based on functional T cell assays, RNA signatures, and 
other parameters that identify patients that are more likely to 
benefit from immune adjuvant therapy, across the heterogeneous 
group of VL–HIV patients.
Timing
Visceral leishmaniasis–HIV coinfection is a dynamic process 
with diverse stages of infection and regardless of choice of 
immunomodulatory intervention, timing will be critical to 
success. For instance, high IL-17 levels appeared protective for 
early VL progression, but its role is still debatable in chronic 
infection. The optimal timing of immunotherapy among 
HIV-coinfected adults in regard to HIV stage and receipt of 
antiretroviral therapy also remain important unanswered ques-
tions. Most benefit is probably to be gained in early stages of 
HIV infection as well as in under-therapy suppressed patients, 
who are able to effectively respond to immunomodulators. 
Therefore, we would argue for a primary evaluation of novel 
approaches in stable ART patients that have a somewhat 
reconstituted CD4+ T cell immunity and suppressed viral load, 
including frequent monitoring of blips in viral load and CD4+ 
T cell count. It remains to be investigated whether HIV patients 
with a severe suppression in T cell immunity are also able to 
respond to immune stimulators or whether virological suppres-
sion first has to be prioritized to enable T cell responsiveness.
Targeted Strategies
The delivery system is also an important part of an immune-based 
strategy and implementation of various novel approaches based 
on liposomes, electroporation, dendrimers, carbon nanotubes, 
etc., can boost efficacy (92). For instance, as an alternative for 
broad cytokine adjuvants, more effective and tolerable approaches 
are being explored like encapsulation in micro or nanoparticles, 
restricting the delivery to APCs and/or the co-delivery with 
another immunomodulatory molecule via transducing vectors. 
Similar techniques such as microRNA or small interference RNA-
based therapy could be explored, but these novel drugs will be 
most likely unaffordable in most countries where the disease is 
endemic.
Accesibility
The target population is largely living in very rural and/or poor 
areas, where a highly controlled clinical trial setting can be chal-
lenging and costly to implement. It will be imperative to strengthen 
human and infrastructural capacity in disease endemic areas to 
ensure a sustainable base for immunotherapeutic research and 
to assess safety and efficacy of novel interventions. Moreover, 
designed therapeutics should become affordable and accessible 
to the patient population, suggesting innovative low-resource-
demanding methods ideally without the need of a cold chain.
Conclusion
To advance the development of immunomodulatory approaches 
for VL–HIV coinfection, a more detailed account of the immuno-
logical status induced by the coinfection and surrogate markers of 
cure and protection are still required, as a forerunner to inclusion 
of such patients in clinical intervention studies. The main limita-
tion for comprehensive immunological research is, however, the 
need for human samples of longitudinal studies and trials in (often 
very remote) low-resource settings. With more research aimed at 
discovering key synergistic pathways of immune cell cross-talk 
and renewed efforts to translate these findings into effective treat-
ment modalities that target Leishmania without promoting HIV 
replication, the goal of improved patient outcome and clinical 
management of this neglected population may be achievable.
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